Neuren Pharmaceuticals Updates on Ongoing Share Buy-Back Program

Neuren Pharmaceuticals Limited ( (AU:NEU) ) has shared an update.

Neuren Pharmaceuticals Limited announced an update regarding its ongoing on-market buy-back program. As of May 2, 2025, the company has repurchased a total of 2,910,919 ordinary fully paid securities, with an additional 22,453 securities bought back on the previous day. This buy-back initiative is part of Neuren’s strategy to optimize its capital structure and potentially enhance shareholder value.

More about Neuren Pharmaceuticals Limited

Neuren Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development of therapies for neurological disorders. The company is known for its work on treatments aimed at conditions such as Rett syndrome and Fragile X syndrome, positioning itself as a key player in the niche market of neurological therapeutics.

YTD Price Performance: -6.57%

Average Trading Volume: 1,250

Technical Sentiment Signal: Hold

Current Market Cap: $956.5M

For detailed information about NEU stock, go to TipRanks’ Stock Analysis page.